Project Grant DP5OD039431
Award Date 8/20/25
Completion Date 7/31/30
Dollars Obligated $412K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The U.S. National Cancer Institute (NCI) awarded a $693,781 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), effective April 14, 2025. The grant supports research focused on "Harnessing Mutant IDH1 as a Therapeutic Target in Liver Cancer and Other Solid Malignancies." The key objectives are to understand how IDH1-inhibiting medicines slow cancer growth, why resistance...
- This federal Project Grant award for $659,325.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to understand the role of mutant IDH1 in glioma pathophysiology and immune response mechanisms. The research will use a novel murine glioma model developed by incorporating genetic lesions into neural progenitor cells using the...
- This federal Project Grant award of $656,879.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research at the University of Texas Southwestern Medical Center (UT Southwestern) to study the mechanisms by which isocitrate dehydrogenase (IDH) mutations contribute to the initiation and progression of lower grade gliomas. The research...
- This federal Project Grant award of $2,467,799 from the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), is supporting research at Washington University to understand the role of the myeloid cell metabolic enzyme wild-type IDH1 (WT-IDH1) in glioblastoma. The research aims to investigate how targeting WT-IDH1 in tumor-associated myeloid cells can reprogram the tumor microenvironment to enhance anti-tumor immune responses and slow glioblastoma growth. This 4-year...
- The University of Massachusetts Medical School (UMMS) received a $196,029 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to conduct research on "Deciphering the Immune Evasion Mechanisms in Mutant IDH1 Cancer". The project aims to investigate how mutations in the IDH1 gene create an immunosuppressive tumor microenvironment in intrahepatic cholangiocarcinoma, with the goal of advancing the mechanistic understanding and therapeutic...
- This Project Grant award, titled "Unlocking the Immunobiology of Conventional Dendritic Cells to Augment T Cell Activation in Glioblastoma", is funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award provides $628,373 to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct research focused on...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to develop and evaluate a therapeutic strategy that combines a brain-penetrant glyoxalase 1 (GLO1) inhibitor with radiation for the treatment of isocitrate dehydrogenase-mutant (IDHm) gliomas, one of the deadliest forms of brain cancer. The project aims to mechanistically validate reactive metabolite...
- The federal Project Grant award with ID HT94252410711, titled "TARGETING HETEROGENEITY IN NF2-MUTANT TUMORS," was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,568,220.00 grant, with a performance period from Sep 15, 2024 to Sep 14, 2027, was awarded to The General Hospital Corporation's Research Management Division, doing business as Massachusetts General Hospital (MGH). Through this funding, MGH will conduct...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $198,000.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on "Precision Medicine for Non Small Cell Lung Cancer Brain Metastases: Noninvasive Detection of Targetable Mutations Using Radiosurgery." The award period runs from May 1, 2025 to April 30, 2026. As a renowned academic...
- This $484,803 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by Mayo Clinic to elucidate the genetics underlying glioma risk and outcomes. The project aims to leverage germline and somatic genetic data to: Evaluate the clinical utility of germline variants associated with glioma risk and specific molecular subtypes through polygenic risk models. Determine if germline variants can predict the presence of clinically...